Keyphrases
Deficiency Diseases
100%
Lung Disease
100%
Augmentation Therapy
100%
Alpha-1 Antitrypsin Deficiency
100%
Alpha-1 Antitrypsin
100%
Active Groups
75%
Confidence Interval
75%
Placebo Groups
75%
Cochrane
50%
Group Differences
50%
Treatment Costs
25%
Forced Expiratory Volume in 1 Second (FEV1)
25%
Clinical Benefit
25%
Lung Density
25%
Lung Infection
25%
Mortality Data
25%
Cystic Fibrosis
25%
Genetic Disease
25%
PubMed
25%
Quality of Life
25%
Randomized Trial
25%
Placebo
25%
Risk of Bias
25%
Carbon Dioxide
25%
First Trial
25%
Genetic Variants
25%
Ex-smokers
25%
Absence of Evidence
25%
Chronic Obstructive Pulmonary Disease
25%
Ultra-high Risk
25%
Serious Adverse Events
25%
Hospital Admission
25%
Inherited Disorders
25%
Never-smokers
25%
Computed Tomography
25%
Medicine and Dentistry
Silo-Filler's Disease
100%
Alpha 1 Antitrypsin
100%
Alpha 1-Antitrypsin Deficiency
100%
Placebo
100%
Diseases
50%
Group Trial
25%
Smoke
25%
Lung
25%
Cystic Fibrosis
25%
Quality of Life
25%
Carbon Monoxide
25%
Health Care Cost
25%
Smoking
25%
Chronic Obstructive Pulmonary Disease
25%
Adverse Event
25%
Genetic Disorder
25%
Lung Infection
25%
Forced Expiratory Volume
25%
Nursing and Health Professions
Lung Disease
100%
Alpha 1 Antitrypsin
100%
Alpha 1 Antitrypsin Deficiency
100%
Placebo
100%
Confidence Interval
75%
Diseases
50%
Obstructive Lung Disease
25%
Genetic Disorder
25%
Carbon Monoxide
25%
X-Ray Computed Tomography
25%
Adverse Event
25%
Quality of Life
25%
Medline
25%
Lung Infection
25%
Cystic Fibrosis
25%
Forced Expiratory Volume
25%
Pharmacology, Toxicology and Pharmaceutical Science
Alpha 1 Antitrypsin Deficiency
100%
Placebo
100%
Alpha 1 Antitrypsin
100%
Lung Disease
100%
Diseases
50%
Cystic Fibrosis
25%
Group Trial
25%
Chronic Obstructive Lung Disease
25%
Adverse Event
25%
Carbon Monoxide
25%
Lung Infection
25%
Genetic Disorder
25%